SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wärnberg Fredrik) "

Sökning: WFRF:(Wärnberg Fredrik)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Norenstedt, Sophie, et al. (författare)
  • Breast cancer associated with primary hyperparathyroidism : a nested case control study
  • 2011
  • Ingår i: Clinical Epidemiology. - 1179-1349 .- 1179-1349. ; 3, s. 103-106
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>BACKGROUND:</strong> Primary hyperparathyroidism (pHPT) is associated with an increased risk of developing breast cancer, but little is known about the underlying factors. The aim of this study was to compare women with a history of pHPT and a reference population in terms of standard factors predictive of prognosis and response to therapy for breast cancer.</p> <p><strong>METHODS:</strong> We analyzed data collected from the National Swedish Cancer Register and from two regional oncologic center registries. Seventy-one women with breast cancer and a history of parathyroid adenomectomy were compared with 338 matched controls with breast cancer only. Tumor size, stage, hormone receptor status, lymph node status, cause of death, and cumulative survival were analyzed.</p> <p><strong>RESULTS:</strong> The mean age was 69 ± 11 years (95% confidence interval [CI]: 68-70) in both groups and the mean time interval between the parathyroid surgery and breast cancer diagnosis was 91 ± 68 months (95% CI: 72-111). There were no differences between the two groups regarding size, stage, lymph node metastases, or survival, but none of the cases with a history of pHPT were found in Stage III or IV.</p> <p><strong>CONCLUSION:</strong> In conclusion, factors predictive of prognosis and response to therapy in women with a history of pHPT and breast cancer are similar to those in breast cancer patients without pHPT.</p>
  •  
2.
  • Wärnberg, Fredrik, et al. (författare)
  • Long-Term Outcome After Retro-Areolar Versus Peri-Tumoral Injection of Superparamagnetic Iron Oxide Nanoparticles (SPIO) for Sentinel Lymph Node Detection in Breast Cancer Surgery.
  • 2019
  • Ingår i: Annals of Surgical Oncology. - 1068-9265 .- 1534-4681. ; 26:5, s. 1247-1253
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>BACKGROUND/OBJECTIVE:</strong> SPIO is effective in sentinel node (SN) detection. No nuclear medicine department is needed, and no allergic reactions have occurred. This study aimed to compare retro-areolar and peri-tumoral SPIO injections regarding skin staining, detection rates and number of SNs.</p><p><strong>METHODS:</strong> Data on staining size, intensity and cosmetic outcome (0-5; 0 = no problem) were collected by telephone interviews with 258 women undergoing breast conservation. SN detection and the number of SNs were prospectively registered in 332 women.</p><p><strong>RESULTS:</strong> After retro-areolar and peri-tumoral injections, 67.3% and 37.8% (p &lt; 0.001) developed skin staining, with remaining staining in 46.2 vs. 9.4% after 36 months (p &lt; 0.001). Initial mean size was 16.3 vs. 6.8 cm (p &lt; 0.001) and after 36 months, 6.6 vs. 1.8 cm<sup>2</sup> (p &lt; 0.001). At 75.1% of 738 interviews, staining was reported paler. After retro-areolar injections, cosmetic outcome scored worse for 2 years. The mean (median) scores were 1.3(0) vs. 0.5(0) points, and 0.2(0) vs. 0.1(0) points, at 12 and 36 months, respectively. Overall detection rates were 98.3% and 97.4% (p = 0.43) and the number of SNs 1.35 vs. 1.57 (p = 0.02) after retro-areolar and peri-tumoral injections. Injection, regardless of type, 1-27 days before surgery increased detection rates with SPIO, 98.0% vs. 94.2% (p = 0.06) ,and SN numbers, 1.56 vs. 1.27 (p = 0.003).</p><p><strong>CONCLUSION:</strong> SPIO is effective and facilitates planning for surgery. Peri-tumoral injection reduced staining with a similar detection rate. Staining was not considered a cosmetic problem among most women. Injecting SPIO 1-27 days before surgery increased the detection rate by 3.8% and increased the number of SNs by 0.3.</p>
  •  
3.
  •  
4.
  •  
5.
  • Barnes, N. L. P., et al. (författare)
  • Cyclooxygenase-2 inhibition : effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer
  • 2007
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 96:4, s. 575-582
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Cyclooxygenase-2 (COX-2) is associated with poor-prognosis breast cancer. We used a nude mouse xenograft model to determine the effects of COX-2 inhibition in breast cancer. Oestrogen receptor (ER)-positive MCF7/HER2-18 and ER-negative MDAMB231 breast cancer cell lines were injected into nude mice and allowed to form tumours. Mice then received either chow containing Celecoxib (a COX-2 inhibitor) or control and tumour growth measured. Tumour proliferation, apoptosis, COX-2, lymphangiogenesis and angiogenesis were assessed by immunohistochemistry (IHC), Western blotting or Q-PCR. Celecoxib inhibited median tumour growth in MCF7/HER2-18 (58.7%, P=0.029) and MDAMB231 (46.3%, P=0.0002) cell lines compared to control. Cyclooxygenase-2 expression decreased following Celecoxib treatment (MCF7/HER2-18 median control 65.3% vs treated 22.5%, P=0.0001). Celecoxib increased apoptosis in MCF7/HER2-18 tumours (TUNEL 0.52% control vs 0.73% treated, P=0.0004) via inactivation of AKT (median pAKT(ser473) 57.3% control vs 35.5% treated, P=0.0001--confirmed at Western blotting). Q-PCR demonstrated decreased podoplanin RNA (lymphangiogenesis marker) in the MCF7/HER2-18 - median 2.9 copies treated vs 66.6 control (P=0.05) and MDAMB231-treated groups--median 160.7 copies vs 0.05 control copies (P=0.015), confirmed at IHC. Cyclooxygenase-2 is associated with high levels of activated AKT(ser473) and lymphangiogenesis in breast cancer. Cyclooxygenase-2 inhibition decreases tumour growth, and may potentially decrease recurrence, by inactivating AKT and decreasing lymphangiogenesis.</p>
  •  
6.
  •  
7.
  • Berglund, Anders, et al. (författare)
  • Impact of comorbidity on management and mortality in women diagnosed with breast cancer
  • 2012
  • Ingår i: Breast Cancer Research and Treatment. - 0167-6806 .- 1573-7217. ; 135:1, s. 281-289
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>To investigate associations between comorbidity burden, management, and mortality in women with breast cancer. A total of 42,646 women diagnosed with breast cancer between 1992 and 2008 were identified in two Clinical Quality Registers in Central Sweden. Breast cancer-specific, conditional breast cancer, competing-cause and all-cause mortality were estimated in relation to comorbidity burden assessed by the Charlson comorbidity index. All analyses were stratified by stage at diagnosis using competing risk analyses, and all-cause mortality was estimated as a function of follow-up time. Following adjustment for age and calendar period, breast conserving surgery was significantly less likely to be offered to women with severe comorbidity (OR 0.63; 95 % CI 0.58-0.69). Similarly, the proportion treated with radiotherapy, tamoxifen, or chemotherapy was lower in women with severe compared to those with no comorbidity. In women with early stage disease, breast cancer-specific mortality was higher among patients with severe comorbidity (sHR 1.47; 95 % CI 1.11-1.94). In all stages of breast cancer, conditional breast cancer and competing-cause mortality were elevated in women with severe comorbidity. For all stages, the relative risk of all-cause mortality between women with severe versus no comorbidity varied by time since diagnosis, and was most pronounced at early follow-up. Comorbidity affects treatment decisions and mortality. In women with early stage breast cancer, severe comorbidity was associated not only with conditional breast cancer, competing-cause and all-cause mortality, but also breast cancer-specific mortality. The observed differences in breast cancer-specific mortality may be due to less extensive treatment, impaired tumor defense and differences in general health status and lifestyle factors.</p>
  •  
8.
  • Bindra, Amarinder, et al. (författare)
  • Search for DNA of exogenous mouse mammary tumor virus-related virus in human breast cancer samples
  • 2007
  • Ingår i: Journal of General Virology. - 0022-1317 .- 1465-2099. ; 88, s. 1806-1809
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Earlier reports of a human exogenous retrovirus (HMTV) related<sup> </sup>closely to mouse mammary tumor virus (MMTV) led us to search<sup> </sup>for these viral sequences in breast cancer tissues and normal<sup> </sup>tissues. A real-time PCR was developed based on MMTV and published<sup> </sup>HMTV envelope sequences. The real-time PCR method can detect<sup> </sup>one to ten copies of MMTV target DNA. Tissue samples were collected<sup> </sup>prospectively from 18 breast cancer patients and 11 non-malignant<sup> </sup>control cases, as well as peripheral blood leukocytes from the<sup> </sup>same women. Despite the high sensitivity of the real-time PCR<sup> </sup>method used, none of the samples were positive for HMTV DNA<sup> </sup>or RNA. The absence of HMTV DNA in both breast cancer samples<sup> </sup>and controls indicates either that the concentration of putative<sup> </sup>HMTV DNA in the breast cancers was too low for detection or<sup> </sup>that it did not exist there.</p>
  •  
9.
  •  
10.
  • Borgquist, Signe, et al. (författare)
  • The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
  • 2015
  • Ingår i: BMC Cancer. - BioMed Central (BMC). - 1471-2407. ; 15
  • Tidskriftsartikel (refereegranskat)abstract
    • HER2 is a well-established prognostic and predictive factor in invasive breast cancer. The role of HER2 in ductal breast carcinoma in situ (DCIS) is debated and recent data have suggested that HER2 is mainly related to in situ recurrences. Our aim was to study HER2 as a prognostic factor in a large population based cohort of DCIS with long-term follow-up.
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (20)
Typ av publikation
tidskriftsartikel (85)
doktorsavhandling (4)
annan publikation (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (71)
övrigt vetenskapligt (25)
populärvet., debatt m.m. (1)
Författare/redaktör
Wärnberg, Fredrik, (83)
Amini, Rose-Marie (18)
Zhou, Wenjing (17)
Karakatsanis, Andrea ... (14)
Blomqvist, Carl (13)
Abdsaleh, Shahin, (10)
visa fler...
Jirström, Karin, (10)
Holmberg, Lars, (9)
Fjällskog, Marie Lou ... (8)
Garmo, Hans (8)
Bergh, Jonas (8)
Bergkvist, Leif, (7)
Sollie, Thomas (7)
Ringberg, Anita (6)
Sund, M (6)
Jirstrom, Karin, (6)
Bergh, J, (5)
Norderyd, Ola (5)
Borgquist, Signe, (5)
Lambe, Mats (5)
Eriksson, S. (5)
Eriksson, Staffan, (5)
Koch, Göran (5)
Fredriksson, I, (5)
Rolander, Bo, (5)
Sandelin, Kerstin (5)
Mattsson, Anna (5)
Frisk, Fredrik, (5)
Sørlie, Therese (5)
Brahm, Carl-Otto, (5)
Ullbro, Christer (5)
Lindfors, Ninita (5)
Mohammed, I. (5)
Wadsten, C (5)
Børresen-Dale, Anne- ... (4)
Warnberg, F (4)
Lindmark, Ulrika, 19 ... (4)
Adolfsson, Jan (4)
Johansson, Christine ... (4)
Sund, Malin (4)
Holmqvist, Marit (4)
Butt, Salma, (4)
Stålberg, Peter (4)
Karlsson, Per (4)
Daskalakis, Kosmas, (4)
Anastassaki Köhler, ... (4)
Nydell Helkimo, Anna (4)
Olofsson, Helena, (4)
Kristensen, Vessela ... (4)
Wärnberg Gerdin, Eli ... (4)
visa färre...
Lärosäte
Uppsala universitet (71)
Umeå universitet (7)
Lunds universitet (7)
Karolinska Institutet (4)
Karlstads universitet (3)
Högskolan i Jönköping (2)
visa fler...
Örebro universitet (1)
visa färre...
Språk
Engelska (90)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (92)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy